Millie Bobby Brown and several of her “Stranger Things” castmates spent their Easter getting vaccinated.
Millie Bobby Brown and several of her “Stranger Things” castmates spent their Easter getting vaccinated.
When you're waiting for a vaccine, money spent on books doesn't count, okay? Originally Appeared on Glamour
Here's what to do if you test positive for the coronavirus before your second Pfizer or Moderna shot.
This week’s episode of the Checking In podcast is all about COVID-19 vaccines.
A new HIV vaccine has shown a 97% response rate in Phase I clinical trials. Currently, HIV affects more than 38 million people globally. If approved, this vaccine could become the first stage of a multi-step strategy to combat HIV and other viral diseases. And the next phase of clinical trials will begin to incorporate technology developed by Moderna, which was also used in Moderna’s mRNA COVID-19 vaccine. The vaccine successfully stimulated the production of rare immune cells needed to generate antibodies against HIV, which causes AIDS and interferes with the body’s ability to fight infections, reported non-profit organizations IAVI and Scripps Research. “This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well,” said William Schief, a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center (NAC). The vaccine is meant to act as an immune primer that triggers the activation of cells via a process called “germline-targeting,” according to The European Pharmaceutical Review. Its purpose is to act as the first step in a vaccine regimen that would elicit the production of a variety of broadly neutralizing antibodies (bnAbs). Stimulating this type of response has reportedly been pursued in HIV research for decades because it could target a wide range of HIV variants. The surface of HIV has proteins called spikes. Antibodies generated by a future version of this vaccine would disable them from entering human cells. While a 97% response rate is exceptionally positive, it is important to note that this is representative of an initial study of 48 adult volunteers who enrolled in the trial. Phase I testing marks the first time a vaccine is tested on a small group of adults in order to evaluate its safety and measure immune responses. This vaccine will undergo another Phase I clinical trial. After all Phase I trials are complete, the next step is Phase II trials. According to the Centers for Disease Control and Prevention, Phase II trials expand the clinical study and give the vaccine to people similar to those for whom the new vaccine is intended. By Phase III, the vaccine is given to thousands of people to test efficacy and safety before being submitted for a rigorous approval and licensing process. Often, vaccines undergo a Phase IV in which the vaccine would go through a formal, ongoing study even after it’s been approved. “As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells,” the organizations said in a joint statement. “Using mRNA technology could significantly accelerate the pace of HIV vaccine development.” This article previously stated that the HIV vaccine already incorporated Moderna technology. It has been updated to reflect that the Moderna technology will be incorporated in the next round of clinical trials. Refinery29 regrets the error. Like what you see? How about some more R29 goodness, right here?What Happens If You Get COVID Between Vaccines?The Biggest Dating App Flex Is Being Vaccinated9 Common Vaccine Myths, Debunked
Pfizer asked the FDA for emergency authorization to start inoculating 12 to 15 year-olds after extremely promising study results.
We consulted science to answer all your burning questions.
In his third Restaurant Diary entry, line cook Peter Steckler explains how the vaccine provided him relief and his restaurant a new influx of customers.
Scientists discovered the technology that fuels COVID-19 vaccines 25 years ago. Now they want to use it to prevent other life-threatening illnesses.
Your immune system is working against the virus even if you do not exhibit any symptoms.
With the pandemic disrupting much of the traditional teen experience, 16-year-olds are encountering a modern new milestone.
On Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration recommended that the United States pause its use of the Johnson & Johnson coronavirus vaccine after multiple instances of “rare and severe” blood clotting were reported. There were six reported cases of blood clots; to compare, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States, making this an incredibly rare reaction. But because we’re dealing with new vaccines and a novel virus, health officials are being extremely cautious, and have concluded that it’s best to stop vaccinating people with the one-shot vaccine for now. Which might leave people who had an appointment to receive the J&J jab wondering: What now? I have a J&J appointment in an hour, and if I don’t get a vaccine because 6 people out of 6 million got blood clots after I was allowed — nay, encouraged — to take hormonal birth control for DECADES, you will be hearing about a tiny little one woman riot.— Emily Dagger (@AbbottRabbit) April 13, 2021 All federal health channels — such as mass vaccination sites and community health centers — are immediately halting administration of the Johnson & Johnson vaccine, for the time being, reports CNN. The CDC and FDA are recommending that states do the same; however, it will be up to each individual state to make that decision, as they are given separate allocations of doses. Right now, all states have halted the use of J&J until there is more information available. But because each state has a different vaccine rollout strategy, they will likely have different ways of dealing with the pause, too. In New York State, for instance, people with appointments to get the J&J vaccine will instead receive Pfizer, according to a statement from Howard Zucker, MD, the NYS Department of Health Commissioner. Many other states seem to be following suit, and plan to give people with existing appointments the Moderna or Pfizer vaccine instead. Today our Public Health team will follow CDC guidelines and pause Johnson & Johnson distribution. If you’re scheduled to receive the J&J vaccine today, please **do not cancel your appointment** We will offer you Pfizer at NRG and Moderna at our mobile sites instead.— Lina Hidalgo (@LinaHidalgoTX) April 13, 2021 But some locations are having to reschedule or cancel existing appointments now that the J&J vaccine is temporarily unavailable. In New Jersey, Gov. Phil Murphy announced: “J&J vaccine appointments will be canceled or put on hold at all New Jersey vaccination sites until further notice. The New Jersey Department of Health will work with all vaccination sites to make arrangements for the administration of an alternative two-dose vaccine.” But many sites that are distributing vaccines throughout the state have said that they won’t be canceling appointments and will be offering alternate vaccines instead. Dr. Janet Woodcock, the acting commissioner of the FDA, said in a news conference that the pause is expected to be short, only “a matter of days,” depending on on what they learn from thoroughly investigating each of the cases. The CDC is expected to convene an Advisory Committee on Immunization Practices (ACIP) to review all six instances before deciding whether the vaccine should continue to be distributed to all adults, or certain age groups or populations. Currently, there are approximately nine million more doses of the Johnson & Johnson vaccine that have been shipped out to various states, according to data from the CDC. In a statement sent to Refinery29, Johnson & Johnson said: “We are aware of the extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine…We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public.” If you have an appointment to receive the Johnson & Johnson vaccine in the coming days, keep an eye on your email and your phone to see if you receive a cancelation or rescheduling notification. You can also call your state’s vaccine hotline or your vaccine site, if you have the number, to ask for next steps. But for now, it looks like there’s a good chance you can still show up to your appointment and receive a two-dose mRNA vaccine instead of the J&J one-shot. Additional reporting by Molly Longman. Like what you see? How about some more R29 goodness, right here?Had the Johnson & Johnson Vaccine? Don't PanicJohnson & Johnson's Vaccine Isn't "Less Effective"I Helped Create The Johnson & Johnson Vaccine
By now, you've probably heard all about the side effects of the COVID-19 vaccine: sore arm, fever, chills, fatigue, headache, nausea, and more. The side effects vary depending on which vaccine you get, and they also are supposedly worse after the second shot, if you are younger, and/or if you had previously had COVID.
Many of us want to know, but we aren't quite sure how to ask. We talked to experts about the best ways to approach the question.
We also found out what to do if you misplace your card.
No, getting vaccinated won't impact your fertility.
As of Friday, roughly 20% of people in the U.S. have been fully vaccinated against COVID-19, according to the Centers for Disease Control and Prevention (CDC). With millions of people receiving at least one of the three approved vaccines each day, widespread immunity against the coronavirus is slowly becoming a reality. But, as more vaccinations are rolled out and life inches back to pre-pandemic times, the question of how long that immunity will last after the final shot is on a lot of people’s minds. According to new research from Pfizer and Moderna, it looks like COVID-19 immunity will last at least six months in fully vaccinated people, though studies are ongoing. In a statement released by Pfizer-BioNTech on Thursday, immunity against the coronavirus is confirmed to last at least half a year for people who have been fully vaccinated with the Pfizer shot. The company, following an observation of 927 symptomatic cases during its phase 3 study, concluded that its vaccine remained 91.3% effective against the virus for up to six months after. Pfizer also confirmed that the COVID-19 vaccine was 100% effective against severe disease, as defined by the CDC; 95.3% effective against severe COVID-19 symptoms, as defined by the U.S. Food and Drug Administration (FDA); and 100% effective against the highly transmissible B.1.351 variant of the coronavirus. The Moderna vaccine also appears to remain effective in fighting against COVID-19 for at least six months after the second shot, according to an April 6 report in The New England Journal of Medicine. The vaccine showed a 94% efficacy in the company’s own phase 3 trial, in which 33 adults were tested. Moderna will continue to monitor the subjects’ antibody levels in the coming months. What will these findings mean for future booster shots and prolonging the vaccine’s effectiveness? Given the still very new nature of this data, medical experts just aren’t sure yet. For the Moderna vaccine, scientists contributing to The New England Journal of Medicine reported that they are “determining the effect of a booster dose to extend the duration and breadth of activity against emerging viral variants.” Pfizer also appears to be determining the need for a booster shot; its Thursday press release includes mention of “a potential second booster dose of BNT162b2 [the Pfizer vaccine sequence] and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence.” Experts will no doubt advise people who have been vaccinated to receive booster shots if and when they are developed. Until those shots become reality, those of us who have been partially or fully vaccinated can rest easy knowing that we remain between 80 to 90% protected against COVID-19 for the time being. Like what you see? How about some more R29 goodness, right here?COVID Vaccine Booster Shots Are ComingPeople Are Having Period Symptoms Post VaccineThe COVID-19 Vaccines May Have Surprising Benefits
Cerebral venous sinus thrombosis is a type of blood clot seen in five per 1 million people a year. Johnson & Johnson saw six cases out of 6.8 million.
Here's what the 6-month efficacy mark really means.
Many parents are still hesitant to have their children vaccinated against COVID-19.
Health officials called for an immediate pause on use of the Johnson & Johnson COVID-19 vaccine Tuesday morning. This decision came after six recipients in the U.S. developed a rare disorder involving blood clots within about two weeks of receiving the one-dose vaccine. All six of these recipients identified as women and were between the ages 18 and 48. One woman has died and a second person in Nebraska is in critical condition in the hospital. Since the J&J vaccine was approved for emergency use in America by the Food and Drug Administration, nearly seven million people in the U.S. have received this vaccine. “We are recommending a pause in the use of this vaccine out of an abundance of caution,” Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, and Anne Schuchat, MD, principal deputy director of the Centers For Disease Control and Prevention, said in a joint statement. “Right now, these adverse events appear to be extremely rare.” On Wednesday, the CDC will convene an Advisory Committee on Immunization Practices (ACIP) to review these six cases and discuss whether they’re significant. After careful examination by the FDA and CDC, the health agencies will decide whether the vaccine should continue to be distributed to all adults, or if the authorization should be limited to certain populations or age groups. Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution.— U.S. FDA (@US_FDA) April 13, 2021 The cases of blood clots, which occurred in conjunction with low platelet counts, first came to light late last week, and on Friday, Johnson & Johnson told Reuters they were aware of the issue, and were working with regulators to look over the data. In a statement sent to Refinery29, Johnson & Johnson said: “We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine… We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public.” The company added that it had also decided to proactively delay the vaccine rollout in Europe. This news is being announced amid a surge in COVID-19 cases. The virus thus far has killed more than 2.9 million worldwide and can cause long-term health concerns. The national vaccine rollout has been largely well-received, and although vaccine hesitancy is less prevalent than it was in December, hesitancy or resistance to vaccination is still widespread enough to have experts concerned. Some experts say the fact that the CDC and FDA have called for a pause on the J&J vaccine is a sign that our health systems are working, and of how seriously the agencies are taking safety. “This tells me that any possible adverse effects are getting reported up the chain of a command,” says Paul Pottinger, MD, a professor specializing in infectious disease at the University of Washington School of Medicine. “Those six cases, it’s a little less than one in a million, it’s incredibly rare, but the agencies are hitting pause so they can look at the data and decide if the association is true…. The overall safety of the vaccine has been shown to be strong, and the effectiveness is still very strong, so I’m hopeful the pause will be lifted so they can start getting the vaccine out and saving lives.” “I know there are people who have gotten the vaccine who are probably very concerned,” Dr. Schuchat said in an FDA and CDC briefing Tuesday morning. “For people who got the vaccine over a month ago, the risk is very low at this time. For people who recently got the vaccine within the last couple weeks, they should be aware to look for any symptoms.” If you received the Johnson & Johnson vaccine, Dr. Pottinger says that there’s no need to panic. But if you have any issues within three weeks of vaccination, report them to your doctor. Dr. Pottinger notes that in the 12 to 48 hours after the initial shot, it’s common to experience side effects such as headaches, fatigue, and muscle aches, and he emphasizes that it would be “incredibly rare” to experience this and have the reason be blood clots. But to be on the safe side, if you develop symptoms, especially severe headaches, leg pain, abdominal pain, or shortness of breath, anytime within a month of getting the vaccine, call your doctor or go to urgent care and tell them you’ve been vaccinated in the last month, he says, echoing FDA and CDC guidance. “If you’ve had the Johnson & Johnson vaccine, I’d say, ‘Congratulations,’ because that means you’re protected from a severe disease that can lead to hospitalization and death,” he adds. There have been similar concerns in Europe and other countries about the COVID-19 vaccine developed by Oxford University and AstraZeneca researchers, which hasn’t been authorized yet in the U.S. It’s unclear exactly why these vaccines may cause the blood clots. Federal officials noted in their release that the blood clots that people developed after the J&J vaccine were called cerebral venous sinus thrombosis (CVST), which are somewhat rare and require a different treatment than more common clots. “Usually, an anticoagulant drug called heparin is used to treat blood clots,” the statement said. “In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.” There have been no significant safety concerns with the two mRNA vaccines by Pfizer/BioNTech and Moderna. Like what you see? How about some more R29 goodness, right here?What Should I Do With My COVID Vaccine Card?Is It Okay To Delay Your Second Vaccine Shot?So, How Long Does The COVID Vaccine Actually Last?